Results 21 to 30 of about 14,877 (300)

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report

São Paulo Medical Journal, 2017
CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab.
Selim Kul, Muhammet Raşit Sayın
doaj   +1 more source

Cryo-Electron Microscopy Structure of the αIIbβ3-Abciximab Complex

Arteriosclerosis, Thrombosis and Vascular Biology, 2019
Supplemental Digital Content is available in the text. Objective: The αIIbβ3 antagonist antiplatelet drug abciximab is the chimeric antigen-binding fragment comprising the variable regions of murine monoclonal antibody 7E3 and the constant domains of ...
D. Nesic, Yixiao Zhang, A. Spasic, Jihong Li, D. Provasi, M. Filizola, T. Walz, B. Coller   +7 more
semanticscholar   +1 more source

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio

BMC Cardiovascular Disorders, 2006
Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the question of ...
Baur Regine, Müller Lutz von, Alan Mustafa, Voisard Rainer, Hombach Vinzenz   +4 more
doaj   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

Quantitative structural mechanobiology of platelet-driven blood clot contraction. [PDF]

, 2017
Blood clot contraction plays an important role in prevention of bleeding and in thrombotic disorders. Here, we unveil and quantify the structural mechanisms of clot contraction at the level of single platelets.
Alber, Mark S, Kim, Oleg V, Litvinov, Rustem I, Weisel, John W   +3 more
core   +2 more sources

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials

Journal of Interventional Cardiology, 2022
Objectives. This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Background.
Nan Bai, Ying Niu, Ying Ma, Yao-Sheng Shang, Peng-Yu Zhong, Zhi-Lu Wang   +5 more
doaj   +1 more source

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration

Trials, 2009
Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L, Fokkema Marieke L, Kampinga Marthe A, de Smet Bart JGL, Tan Eng S, van den Heuvel Ad FM, Zijlstra Felix   +6 more
doaj   +1 more source

Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention

Platelets, 2022
Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of ...
Pablo Revilla-Martí, Jose A. Linares-Vicente, Ana Martínez Labuena, Octavio Jiménez Melo, Paula Morlanes Gracia, Daniel Meseguer González, Antonela Lukic, Borja Simó Sánchez, Jose R. Ruiz Arroyo   +8 more
doaj   +1 more source

Editor's choice : European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia

, 2020
A
Acosta, Stefan, Azuma, Nobuyoshi, Bastos Gonçalves, Frederico, Björck, Martin, Boyle, Jonathan R., Chakfé, Nabil, Choke, Edward T. C., Cochennec, Frederic, Cohnert, Tina U., de Borst, Gert J., Document Reviewers, Earnshaw, Jonothan J., ESVS Guidelines Committee, Fitridge, Robert A., Forbes, Thomas L., Hamady, Mohamad S., Hinchliffe, Robert, Jongkind, Vincent, Kakkos, Stavros K., Koelemay, Mark J. W., Koncar, Igor, Lindholt, Jes S., Mani, Kevin, Menyhei, Gabor, Munoz, Alberto, Müller-Hülsbeck, Stefan, Rai, Kumud, Sebastian Debus, E., Svetlikov, Alexei V., Tshomba, Yamume, Tulamo, Riikka, van den Berg, Jos C., Vega de Ceniga, Melina, Vermassen, Frank   +33 more
core   +2 more sources

Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE) [PDF]

, 1998
BACKGROUND: In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours
Klootwijk, A.P.J. (Peter), Lenderink, T. (Timo), Meij, S. (Simon), Melkert, R. (Rein), Simoons, M.L. (Maarten)   +4 more
core   +2 more sources